Virion Reports Long-Term Hepatitis B Response in Early Trial
PHILADELPHIA, PA — Virion Therapeutics reported new long-term data showing its experimental hepatitis B immunotherapy, VRON-0200, produced sustained reductions in key disease markers for more than two years after a …
Virion Reports Long-Term Hepatitis B Response in Early Trial Read More